CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals
This article was originally published in The Tan Sheet
Executive Summary
FDA’s position “is neither scientifically justified, logical nor in the interest of the public health,” CRN argues, asking FDA to reverse its position on synthetic botanicals outside the agency’s revision of the NDI draft guidance.